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Introduction
O-GlcNAcylation is a dynamic and reversible post-translational 
modification on serine and threonine residues of intracellular 
proteins. It is catalysed by two enzymes, O-linked N-acetylglu-
cosaminyltransferase (OGT) and β-N-acetylglucosaminidase 
(O-GlcNAcase, OGA), responsible for the addition and removal 
of the O-GlcNAc group, respectively (Hart et al., 2011). 
O-GlcNAcylation modulates several cellular processes, such as 
transcription (Hanover et al., 2012), cell signalling (Muller et al., 
2013; Zachara et al., 2004), and metabolism (Ruan et al., 2013). 
Changes in O-GlcNAc levels are associated with pathologi-
cal conditions including diabetes, neurodegeneration and cancer 
(Issad et al., 2010; Lazarus et al., 2009; Slawson et al., 2010). 
In addition, accumulating evidence suggests that O-GlcNAc 
modification controls the maturation and activation of immune 
cells, including T cells, B cells and macrophages (Golks & 
Guerini, 2008; Li et al., 2019; Machacek et al., 2019).
O-GlcNAcylation has been shown to affect the transforming 
growth factor (TGF)-β-activated kinase 1 (TAK1) signalling 
pathway (Mendoza et al., 2008). The TAK1 pathway regulates 
inflammatory cytokine production and release in response to 
pro-inflammatory and endotoxin stimuli in macrophages and 
innate immune cells. TAK1 forms a functional complex with the 
pseudo-phosphatase TAK1 binding protein-1 (TAB1) and regu-
lates the production of inflammatory molecules through activa-
tion of several mitogen-activated protein kinases (MAPKs) 
including p38α, extracellular signal-regulated kinases (ERKs) 
and c-jun kinases, leading to subsequent activation of downstream 
effectors including the IκB kinases (IKKs) and the transcription 
factor NFκB (Adhikari et al., 2007; Conner et al., 2006; Sato 
et al., 2005; Shibuya et al., 1996; Shim et al., 2005; Wang 
et al., 2001). TAB1 is required for TAK1 activation and 
downstream signalling events. TAK1 activity can be negatively 
regulated by p38α MAPK through a feedback mechanism where 
p38α MAPK phosphorylates TAB1, leading to TAK1 activity 
suppression (Cheung et al., 2003). The TAK1-TAB1 complex has 
been found to be important in vivo for the survival of activated 
macrophages upon lipopolysaccharide (LPS) stimulation and 
for the modulation of immune response in T and B cells (Mihaly 
et al., 2014; Sato et al., 2005).
We previously showed that human TAB1 is modified with 
N-acetylglucosamine (O-GlcNAc) on a single site, Ser395, in 
human cells. O-GlcNAcylation of TAB1 is induced under stress 
conditions and modulates TAK1-mediated cytokine release 
in vitro by increasing TAK1 activation, leading to downstream 
signalling activation and cytokine production in mouse embry-
onic fibroblasts (MEFs) (Pathak et al., 2012). However, the 
in vivo biological significance of this single O-GlcNAc site 
remains to be explored.
Here, we describe the generation of a genome edited consti-
tutive knock-in (KI) mouse model expressing endogenous 
TAB1 lacking the key residue targeted for O-GlcNAcylation. 
The Ser393 site, equivalent to Ser395 in the human TAB1 
sequence, was abolished by introducing a Ser393Ala mutation 
using a classical recombinational approach. We demonstrate 
that this mutation causes the loss of the O-GlcNAc modification 
on TAB1 without affecting TAB1 protein levels or its interac-
tion with TAK1. Homozygous Tab1S393A mice lacking O-GlcNAc 
on TAB1 were viable with no obvious development abnor-
malities. This work provides a platform for exploration of 
O-GlcNAc-dependent functions of TAB1.
Results
Generation of Tab1S393A KI mice
We previously showed that human TAB1 is modified with 
N-acetylglucosamine (O-GlcNAc) on a single site, Ser395 
(Pathak et al., 2012). TAB1 sequence is 97% identical between 
human and mouse. The O-GlcNAc modified Ser395 residue 
in human is conserved in mice and corresponds to the Ser393 
(Figure 1A). The Ser393 residue is the sole reported O-GlcNAc 
site on mouse TAB1 (Alfaro et al., 2012; Trinidad et al., 2012). 
To establish an animal model for investigating the role of 
O-GlcNAc on TAB1 in vivo, we generated TAB1 constitutive 
knock-in (KI) mice carrying a Ser393Ala (S393A) mutation. 
The Tab1 gene is located on mouse chromosome 15 and 
contains 11 exons. The nucleotide sequence encoding the 
amino acid S393 region is located on exon 10. The targeting 
vector contained the translation initiation codon in exon 1 and 
an FRT-flanked puromycin cassette in the intronic sequence 
between exons 9 and 10. The targeted allele was obtained via 
homologous recombination in C57Bl/6NTac ES cells. The 
constitutive KI-point mutation (PM) allele was obtained 
after in vivo Flp recombination (Figure 1B). Positive 
targeted ES cell clones were confirmed by Southern blot anal-
ysis. Correct homologous recombination at 5’ and 3’ sides 
was detected in A-A08, A-C04, B-G06 clones (Figure 2A). 
A single integration site was also confirmed by Southern blot 
analysis using the cag probe, which detects a region located 
within the CAG_PuroR_pA selection cassette. Correct single 
      Amendments from Version 1
This version of the manuscript addresses all comments and 
suggestions by the reviewers. The following changes have been 
made.
Main text: We have clarified that the Ser393 residue on mouse 
TAB1 was the sole reported O-GlcNAc site in vivo with the 
addition of two references. 
Figure 1: We have added an additional panel that shows the 
sequence alignment of mouse and human TAB1 covering the 
C-terminal region.  The panel B (originally panel A) has been 
updated and shows the locations of restrictions sites, primers and 
probes. 
Figure 2: We have added an additional panel that provides the 
DNA sequences of WT and mutant homozygous Tab1S393Amice 
that confirms the presence of the S393A single point mutation and 
we amended the methods section accordingly. 
Figure 3: We have clarified the unit of the Y-axis that shows 
now the normalised weights of the hearts in milligram per g of 
body weight (mg/g) on panel B. We have indicated negative 
(IgG) and positive controls (macrophage lysates) used for 
immunoblots in panel C and D, with the original unedited full gels 
deposited in the Figshare data repository (https://doi.org/10.6084/
m9.figshare.9206567.v1 (Authier, 2019a)). 
Any further responses from the reviewers can be found at the 
end of the article
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Figure 1. Targeting strategy for the generation of constitutive Tab1S393A knock-in (KI) mice. (a) Sequence alignment of human (UniProt 
Q15750) and mouse (UniProt Q8CF89) TAB1 covering the 382-420aa of the C-terminal domain. The human and mouse O-GlcNAc sites 
are reported in blue. (b) Schematic representation of the targeting vector containing a flippase recognition target (FRT)-flanked puromycin 
resistance cassette in intron 9, wild type allele, targeted allele after homologous recombination and the constitutive KI point mutation (PM) 
allele after flippase (Flp) recombination. The locations of the enzymatic restriction sites, primers and probes are also shown.
integration was detected in A-A08, A-C04, B-G06 clones 
(Figure 2B upper panels and left lower panel). The inser-
tion of the point mutation was validated by PCR genotyping 
and detected in all the targeted clones (Figure 2B right lower 
panel). The A-A08 and A-C04 positive clones were injected into 
BALB/c blastocysts to generate chimeric mice. Genotyping 
was performed to identify constitutive KI animals. The pres-
ence of the S393A mutation was confirmed by sequencing 
(Figure 2C). Heterozygous mice were backcrossed to C57BL/6J 
genetic background and maintained as heterozygotes. 
Homozygous Tab1S393A mice were obtained by breeding 
heterozygous offspring. Thus, we successfully generated TAB1 
S393A KI mice lacking the O-GlcNAc site at Ser393.
Tab1S393A KI mice exhibit normal development and survival
We used Tab1S393A/+ heterozygous animals to generate homozygous 
Tab1S393A animals. We obtained 19 WT, 68 Tab1S393A/+ and 17 
Tab1S393A animals from heterozygous pairs. Although deletion of 
TAB1 leads to embryonic lethality and abnormal cardiovascular 
development in mice (Komatsu et al., 2002), the homozygous 
Tab1S393A mice lacking O-GlcNAc on TAB1 were viable and 
developed normally. The Tab1S393A mice appeared healthy and 
similar to WT animals. They showed comparable body weight 
and heart size to WT at three months of age (Figure 3A and 3B; 
Authier, 2019b). In addition, newborn pups were obtained 
by breeding of either male or female homozygous Tab1S393A 
mice with sex-matched WT animals, suggesting that fertility is 
not altered in these animals.
TAB1 is ubiquitously expressed in mammals (Komatsu et al., 
2002; Shibuya et al., 1996). To verify that the S393A mutation 
leads to absence of O-GlcNAcylation of TAB1 in the transgenic 
animals, brain tissues were isolated from WT and Tab1S393A 
mice and TAB1 was immunoprecipitated prior to probing 
with a site specific O-GlcNAc TAB1 antibody (Pathak et al., 
2012). As expected, TAB1 was found glycosylated in WT 
animals, while the S393A mutation led to absence of O-GlcNAc 
on TAB1 in Tab1S393A mice (Figure 3C).
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Figure 2. Generation of correctly targeted embryonic stem (ES) clones bearing the constitutive knock-in (KI) S393A point mutation in 
TAB1. (a) Southern blot of wild-type (WT) and four targeted ES clones (named A-A05, A-A08, A-C04 and A-G06) with 5’ ext and 3’ ext probes 
shows correct homologous recombination at the 5’ and 3’ sides in all clones except for A-C05.The expected molecular weight band for WT 
(W) and the targeted (T) alleles are shown. (b) Southern blot of WT and four targeted ES clones (named A-A05, A-A08, A-C04 and A-G06) 
with the cag probe shows single integration in all clones except for A-C05 (upper left and right panels and lower left panel). The expected 
molecular weight band for the targeted (T) allele is shown. PCR of WT and four targeted ES clones (named A-A05, A-A08, A-C04 and 
A-G06) shows insertion of the point mutation in all targeted clones (lower right panel). The expected molecular weight band for the targeted 
(T) allele is shown. (c) Sequencing of the genomic DNA from WT and KI Tab1S393A mice confirming the S393A single point mutation (in red) in 
KI animal.
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Figure 3. Tab1S393A knock-in (KI) mice lacking O-GlcNAcylation on TAB1 exhibit normal development and retained TAB1-TAK1 
interaction. (a) Body weight of wild-type (WT) and Tab1S393A KI at three months old. Data are expressed as the mean ± SD (WT, n=6; Tab1S393A, 
n=6), Student’s t-test. (b) Heart weight per g of  body weight of WT and Tab1S393A KI at three months old. Data are expressed as the mean ± SD 
(WT, n=6; Tab1S393A, n=6), Student’s t-test. (c) TAB1 protein immunoprecipitation (IP) and blotting using anti-gTAB1 and anti-TAB1 antibodies in 
brain tissues of WT and Tab1S393A mice shows loss of O-GlcNAcylation of TAB1 in Tab1S393A compared to WT animals with similar TAB1 protein 
levels in both genotypes (WT, n=3; Tab1S393A, n=3). (d) TAB1 protein immunoprecipitation (IP) and blotting using anti-TAK1 and anti-TAB1 
antibodies in brain tissues of WT and Tab1S393A mice shows retention of TAB1-TAK1 interaction in both genotypes (WT, n=3; Tab1S393A, n=3). 
IgG: Isotype control; M: mouse macrophage lysate.
We next investigated the impact of the S393A mutation on 
TAB1 protein levels. We observed similar levels of TAB1 pro-
tein expression in WT and Tab1S393A animals suggesting that 
absence of O-GlcNAc of TAB1 has no detectable influence on 
TAB1 protein levels (Figure 3C). Thus, Tab1S393A KI mice lacking 
O-GlcNAc on TAB1 exhibit normal development and survival.
O-GlcNAcylation of TAB1 is not required for its interaction 
with TAK1
TAB1 is found in complex with TAK1 and this interaction is 
required for TAK1-mediated signalling (Mendoza et al., 2008). 
To investigate the effect of loss of O-GlcNAcylation on TAB1 
on the interaction with TAK1, immunoprecipitation analysis was 
performed on brain tissue lysates from WT and Tab1S393A mice. 
We found that TAB1 interacts with TAK1 in both WT and 
transgenic animals, suggesting that O-GlcNAcylation of TAB1 
is not required for its interaction with TAK1 (Figure 3D).
Discussion
Although O-GlcNAcylation was discovered over 30 years 
ago, our knowledge on the biological processes regulated by 
site-specific O-GlcNAcylation of specific proteins is limited. 
Generation of transgenic animal models lacking specific 
O-GlcNAc sites will help to decipher the role of individual 
O-GlcNAc sites and associated mechanisms in physiological and 
pathologic conditions. In the present study we have described the 
generation of a viable constitutive KI mouse model leading to 
loss of the sole reported O-GlcNAc site S393 on TAB1 protein, 
allowing for determining the biological significance of TAB1 
O-GlcNAcylation in vivo.
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A growing body of evidence supports that O-GlcNAcylation 
is an important modulator of the immune response and inflam-
mation (Golks & Guerini, 2008; Golks et al., 2007; Kearse 
& Hart, 1991). However, the role of this modification on 
specific proteins involved in the function and regulation of 
immune cells remains largely unknown. The TAB1-TAK1 
complex regulates the activation, survival and maintenance of 
activated macrophages upon LPS stimulation in vivo (Mihaly 
et al., 2014). O-GlcNAcylation of TAB1 modulates 
TAK1-mediated cytokine release in response to IL-1 stimulation 
or osmotic stress in MEF cells (Pathak et al., 2012). However, 
these pathways have not been investigated in vivo. The Tab1S393 
mice model will allow investigation of the consequences 
of the loss of O-GlcNAc of TAB1 on TAK1 activation and 
signalling in the context of a whole organism.
TAB1 is also involved in a negative feedback loop in which 
p38α MAPK suppresses TAK1 activation through phosphor-
ylation of TAB1 at two residues; Ser423 and Thr431 (Cheung 
et al., 2003). The p38α MAPK is a protein serine-threonine 
kinase involved in signalling pathways induced by stress. 
It is activated by transphosphorylation of the TGY motif 
by MAPK kinases (MKKs) 3, 4 and 6 (Enslen et al., 1998; 
Raingeaud et al., 1996). Besides being a substrate for p38α 
MAPK, TAB1 binds to p38α, leading to its autophosphorylation 
of Thr180 and Tyr182 residues (Ge et al., 2002). This mecha-
nism constitutes an alternative activation pathway for p38α 
MAPK that has been demonstrated to be independent to the 
MKK cascade and does not lead to classical p38α MAPK down-
stream signalling and inflammatory gene expression (Lu et al., 
2006). The autoactivation of p38α MAPK through TAB1 
was observed in pathological conditions, including cardiac 
ischemia and heart failure and has been shown to aggravate 
myocardial injury (De Nicola et al., 2018; Li et al., 2005; 
Shi et al., 2010; Tanno et al., 2003). A recent study has 
demonstrated that the p38α-TAB1 interaction can be targeted 
by small molecules (De Nicola et al., 2018). The same study 
reported that reduction of infarction volume was observed 
in a KI mouse model in which residues located in the p38α 
docking region of TAB1 were mutated to prevent the 
p38α-TAB1 interaction (De Nicola et al., 2018). Thus, the 
development of strategy to target the TAB1-p38α MAPK may 
be therapeutically relevant. Interestingly, the single O-GlcNAc 
site of TAB1 is located within this p38α MAPK binding 
region (DeNicola et al., 2013; Pathak et al., 2012), which is 
required for p38α MAPK activation (Ge et al., 2002). It is 
possible that O-GlcNAc on TAB1 could play a role in modulat-
ing the TAB1-p38α interaction and subsequent p38α MAPK 
autoactivation. In the future, both in vitro and in vivo experi-
ments could be performed to test this hypothesis. Tab1S393A 
mice lacking O-GlcNAc on TAB1 will provide a suitable model 
to investigate the potential effect of this posttranslational 
modification on p38α MAPK signalling during cardiac injury 
in mice.
In our study, we did not observe any obvious phenotype in 
Tab1S393A mice. Given the role of TAB1 in immune response 
and its interactors, it is likely that induction of stress as 
inflammation could reveal potential phenotypes. We conclude 
that this model could be a valuable tool to further investigate the 
functional relevance of the sole reported O-GlcNAcylation 
site of mouse TAB1 in a whole organism at several stages 
of development but also in pathological conditions.
Methods
Ethical statement
All efforts were made to ameliorate any suffering of animals 
by providing appropriate husbandry environment conditions 
(listed below) in accordance with UK and European Union 
regulations. All animal studies were conducted in accord-
ance with the Animal (Scientific Procedures) Act 1986 for 
the care and use of laboratory animals, and procedures were 
carried out under United Kingdom Home Office regulation 
and the project licence PAAE38C7B with approval by the Wel-
fare and Ethical Use of Animals Committee of University of 
Dundee. Mice were humanely killed using a Schedule 1 method 
as soon as any sign of distress or suffering were observed.
Animal source and husbandry
Mice were maintained on a C57BL/6J (Charles River UK) back-
ground and kept in groups of five animals in individually venti-
lated cages at 21°C, 45–65% relative humidity and a 12h/12h 
light/dark cycle under specific-pathogen–free conditions in 
accordance with UK and European Union regulations. Mice 
had access to a mouse house with sizzle-nest material for bedding 
and corn cob for nesting and free access to food (R&M3 pelleted 
irradiated diet) and 0.2 micron sterile filtered water.
Generation of TAB1 constitutive knock-in S393A mice
The TAB1 knock-in (KI) mouse line (C57BL/6NTac-
Tab1tm3593(S393A)Arte) carrying a S393A mutation was generated by 
Taconic Artemis GmbH using the targeting strategy illustrated 
in Figure 1 and based on the NCBI transcript NM_025609_2. 
The targeting vector contains the translation initiation codon 
in exon 1 and also contains a flippase recognition target 
(FRT)-flanked puromycin cassette in intron 9. The targeting vec-
tor was generated using bacterial artificial chromosome (BAC) 
clones from the C57BL/6J RPCIB-731 Tac BAC library and 
transfected by electroporation into C57BL/6NTac embryonic 
stem (ES) cell lines. Recombinant ES cell clones were identi-
fied by Southern blot using external (5’ ext and 3’ ext probes) 
and internal probes (cag). The genomic DNA of the ES cell 
clones were digested with SspI or SphI for the 5’ ext probe and 
analysed for 11.5 kb (SspI digest) or 11.9 kb (SphI digest) 
fragments for the recombinant allele, in addition to 24.2 kb 
(SspI digest) or 9 kb (SphI digest) for the wild-type (WT) 
allele. For the 3’ ext probe, the genomic DNA was digested 
with EcoRI or KpnI and analysed for 13.5 kb (EcoRI digest) or 
12.7 kb (KpnI digest) fragments for the recombinant allele, 
and 10.6 kb (EcoRI digest) or 22.1 kb (KpnI digest) fragments 
for the WT allele. Single integration was also confirmed by 
Southern blot analysis using the cag probe that detects a region 
located within the puromycin selection cassette. The genomic 
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DNA of the ES cell clones was digested with BmtI, EcoRI or 
KpnI restriction enzymes and analysed for single fragments 
of 13.0 kb (BmtI digest), 13.5 kb (EcoRI digest) or 12.7 kb 
(KpnI digest) for the recombinant allele. The insertion of the 
point mutation S393A was validated by PCR genotyping 
using the Puro_R5 and Tab1_30 primers, recombinant Taq 
DNA polymerase (EP0402, Invitrogen) and T100 Thermal 
Cycler (Biorad). The following PCR program was used 
(98 °C for 2 min, 98 °C for 10 sec, 68 °C for 1 min, 40 cycles, 
20 °C for 10 min). Two positive targeted ES cell clones, 
A-A08 and A-C04, were injected using piezo actuated microinjec-
tion pipette with an internal diameter of 12–15 μm into blastocyst 
cells from 10 superovulated 4/5 weeks old BALB/c female mice 
(BALB/cAnNTac, Taconic Artemis GmbH), which were later 
transferred into six pseudopregnant albino NMRI females 
(BomTac:NMRI, Taconic Artemis GmbH) and 31 chimeric 
mice were obtained. Chimerism was measured by coat 
colour contribution of ES cells to BALB/c host (black/white).
Based on visual estimation, three highly chimeric (>75%) 
seven-week-old male mice were selected for further breed-
ing with six age-matched flippase (Flp) deleter C57BL/6 
female mice (C57BL/6-Tg(CAG-Flpe)2 Arte, Taconic Artemis 
GmbH) to remove the selection marker. From this breeding, 28 
mice reached the weaning stage and were used for mouse geno-
typing analysis. Genomic DNA was extracted from ear notches 
collected during the mice identification procedure using an ear 
punch tool (Braintree Scientific, Inc) and analysed by PCR 
using recombinant Taq DNA polymerase (EP0402, Invitrogen) 
and T100 Thermal Cycler (Biorad). The PCR_33 and 
PCR_34 primers amplified bands of 259 bp and 334 bp for the 
WT and the constitutive KI, respectively, using the following 
PCR program (95 °C for 5 min, 95 °C for 30 sec, 60 °C for 
30 sec, 72 °C for 1 min, 35 cycles, 72 °C for 10 min). The 
presence of the point mutation S393A was validated by DNA 
sequencing using the 10597_35 and 10597_36 primers DNA 
amplification and the MT93_dig_seq for the sequencing analy-
sis with Applied Biosystems 3730 device (ThermoFisher Sci-
entific). The primers sequences used were: 5’ ext probe sense: 
AAGCTAAGGTGGCCCTCAAGCAC, 5’ ext probe anti-
sense: CACCGACATTGGCAACGTAGAG, 3’ ext probe sense: 
TCTAAGGTCAGTGCCTATCATACG, 3’ ext probe antisense: 
GGACTTAACCTCTCGCTGTAAGACC, Puro_R5: CCGTAAGT-
TATGTAACGCGGAACTCC, Tab1_30: ATTGGAGGCCAAA-
GATCCAGAGTCC, PCR_33: TCACTTCTCACCCTTACCAGC, 
PCR_34: AATGGGAGGTGAGAGCTCC, 10597_35: AGGCCAC-
TACCTTGGTTTCC, 10597_36: CTGTGTCTAATAAGACTC-
CCTACCC, MT93_dig_seq: TGGAGAATTGGAGGCCAAAG.
Body weight measurement and tissue collection
Heterozygous offspring were used for breeding to generate 
homozygous Tab1S393A mice. WT and homozygous Tab1S393A 
mice were housed together in the same cage in groups of 
five animals. Body weight of six WT mice (three female and 
three male) and six homozygous Tab1S393A mice (four female 
and two male) were measured at three months of age. Data 
collection was performed by an independent observer in a 
blinded manner. For tissue collection, mice were euthanized 
by carbon dioxide gas exposure in a rising concentration and 
brain and heart tissue samples were collected, weighted and 
rapidly snap frozen in liquid nitrogen.
Immunoprecipitation of TAB1 and immunoblotting
Endogenous TAB1 was immunoprecipitated as described pre-
viously (Pathak et al., 2012). Briefly, mouse brain tissue from 
three WT and three homozygous Tab1S393A mice was lysed in 
50 mM Tris-HCl pH 7.4 0.1 mM EGTA, 1 mM EDTA, 1 % 
Triton-X100, 1 mM sodium orthovanadate, 50 mM sodium 
fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1 % 
2-mercaptoethanol supplemented with protease inhibitors (1 mM 
benzamidine, 0.2 mM PMSF and 5 μM leupeptin) and 10 μM 
GlcNAcstatin G. Brain lysate was centrifuged with 14,000 rpm 
for 20 minutes at 4 °C and the protein concentration was deter-
mined with Pierce 660 nm protein assay (22660, Thermofisher 
Scientific). Cleared brain lysate containing 1mg of input protein 
was incubated for two hours at 4 °C with 10 μg of anti-TAB1 
(sheep polyclonal S823A, Division of Signal Transduction 
Therapy, DSTT, University of Dundee) or anti-IgG anti-
body coupled with 10 μl of Dynabeads Protein G (10009D, 
Thermofisher). The beads were washed twice with 1 ml of lysis 
buffer containing 0.25 M NaCl, followed by two washes with 
1 ml of 50 mM Tris/HCl, pH 7.5, 50 mM NaCl and 0.1 % (v/v) 
2-mercaptoethanol. Eluted samples were subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) 
followed by Western blotting (Pathak et al., 2012). 
Membranes were incubated with primary antibodies specific to 
in-house produced gTAB1 (rabbit polyclonal, 1:1000, Univer-
sity of Dundee) (Pathak et al., 2012), TAB1 (sheep polyclonal 
S823A, 1:1000, DSTT) and TAK1 (sheep polyclonal S828A, 
1:1000, DSTT) in blocking buffer, 5 % BSA in TBST (Tris- 
buffered saline with 0.1 % Tween-20) overnight at 4 °C and next 
with IR680 (catalogue # 925-68024, Li-Cor) and IR800 (RRID: 
AB_621848, catalogue # 926-32213, Li-Cor) donkey labelled 
secondary antibodies at room temperature for one hour. Blots 
were imaged using Li-Cor Odyssey infrared imaging system 
(Li-Cor). Original unedited gels and details of the controls used 
can be found here (Authier, 2019a).
Statistical analysis
Statistical analyses were performed with GraphPad Prism ver-
sion 6 software. For pairwise comparisons of WT and Tab1S393A 
body weight and heart size data, the Student’s t-test was used.
Data availability
Underlying data
Figshare: Original unedited gels. https://doi.org/10.6084/
m9.figshare.9206567.v1 (Authier, 2019a)
Figshare: Body weight and heart weight raw data. https://doi.
org/10.6084/m9.figshare.9206546 (Authier, 2019b)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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